Hospital Profile
Name | Emory Hillandale Hospital |
---|
Type | Acute Care Hospital |
---|
Location | 2801 Dekalb Medical Parkway, Lithonia, Georgia |
---|
Ownership | Government - Hospital District or Authority |
---|
Emergency Services | Yes |
---|
Medicare ID (CCN) | 110226 |
Patients' Experience Survey:
Overall Rating of the Hospital:
Willingness to Recommend Hospital:
Yes Patients who reported YES, they would definitely recommend the hospital
Probably Patients who reported YES, they would probably recommend the hospital
No Patients who reported NO, they would probably not or definitely not recommend the hospital
Cleanliness of Hospital Environment:
Always Patients who reported that their room and bathroom were "Always" clean
Usually Patients who reported that their room and bathroom were "Usually" clean
Sometimes or Never Patients who reported that their room and bathroom were "Sometimes" or "Never" clean
Quietness of Hospital Environment:
Always Patients who reported that the area around their room was "Always" quiet at night
Usually Patients who reported that the area around their room was "Usually" quiet at night
Sometimes or Never Patients who reported that the area around their room was "Sometimes" or "Never" quiet at night
Always Patients who reported that their nurses "Always" communicated well
Usually Patients who reported that their nurses "Usually" communicated well
Sometimes or Never Patients who reported that their nurses "Sometimes" or "Never" communicated well
Always Patients who reported that their doctors "Always" communicated well
Usually Patients who reported that their doctors "Usually" communicated well
Sometimes or Never Patients who reported that their doctors "Sometimes" or "Never" communicated well
Responsiveness of Hospital Staff:
Always Patients who reported that they "Always" received help as soon as they wanted
Usually Patients who reported that they "Usually" received help as soon as they wanted
Sometimes or Never Patients who reported that they "Sometimes" or "Never" received help as soon as they wanted
Communication about Medicines:
Always Patients who reported that staff "Always" explained about medicines before giving it to them
Usually Patients who reported that staff "Usually" explained about medicines before giving it to them
Sometimes or Never Patients who reported that staff "Sometimes" or "Never" explained about medicines before giving it to them
Yes Patients who reported that YES, they were given information about what to do during their recovery at home
No Patients who reported that NO, they were not given information about what to do during their recovery at home
Always Patients who "Strongly Agree" they understood their care when they left the hospital
Usually Patients who “Agree” they understood their care when they left the hospital
Sometimes or Never Patients who “Disagree” or “Strongly Disagree” they understood their care when they left the hospital
NPI Associated with the Hospital:
Unlike individual providers, Hospitals may have multiple NPI numbers for example, there can be a separate NPI for each unit within the hospital. We have found possible NPI number/s associated with Emory Hillandale Hospital from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.
NPI Number | 1962403865 |
Organization Name | DEKALB MEDICAL CENTER, INC. |
Doing Business As | EMORY HILLANDALE HOSPITAL |
Address | 2801 Dekalb Medical Pkwy, Lithonia, GA 30058 |
Hospital Type | General Acute Care Hospital |
Phone Number | 404-501-7534 |
News Archive
Research suggests that male mice may be vulnerable to effects of maternal inflammation than females
Johns Hopkins researchers report that fetal mice - especially males - show signs of brain damage that lasts into their adulthood when they are exposed in the womb to a maternal immune system kicked into high gear by a serious infection or other malady.
Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs.
Investigational drug may hold benefit for patients with lung and ovarian cancers
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
Rates of cardiovascular disease increase in Australian winters: Seasonal researcher
Rates of cardiovascular disease increase dramatically in Australian winters because many people don't know how to rug up against the cold, a Queensland University of Technology seasonal researcher has found.
Read more Medical News
› Verified 9 days ago
Structural Quality Measures:
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Research suggests that male mice may be vulnerable to effects of maternal inflammation than females
Johns Hopkins researchers report that fetal mice - especially males - show signs of brain damage that lasts into their adulthood when they are exposed in the womb to a maternal immune system kicked into high gear by a serious infection or other malady.
Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs.
Investigational drug may hold benefit for patients with lung and ovarian cancers
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
Rates of cardiovascular disease increase in Australian winters: Seasonal researcher
Rates of cardiovascular disease increase dramatically in Australian winters because many people don't know how to rug up against the cold, a Queensland University of Technology seasonal researcher has found.
Read more News
› Verified 9 days ago